RRAGB: A Potential Drug Target and Biomarker for various Diseases

Target Name: RRAGB

NCBI ID: G10325

RRAGB

RRAGB: A Potential Drug Target and Biomarker for various Diseases

Ras-related GTP-binding protein (RRAGB) is a protein that plays a critical role in cell signaling and development. It is a member of the G protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that regulate various cellular processes. RRAGB is characterized by its unique ability to bind GTP with high affinity and its critical role in the regulation of cell proliferation, differentiation, and survival.

RRAGB is a protein that is expressed in many different tissues and cells throughout the body. It is highly expressed in the brain, where it is involved in the regulation of neuronal signaling and synaptic plasticity. It is also expressed in other tissues, including the eye, where it is involved in the regulation of sensory perception and neural signaling.

RRAGB is a protein that can modulate the activity of various GPCRs, including the beta2 adrenergic receptor (??2AR), which is involved in the regulation of cardiovascular function and stress responses. It is well established thatRRAGB plays a critical role in the regulation of??2AR signaling and that its function is disrupted in a variety of diseases, including heart failure, hypertension, and neurodegenerative diseases.

RRAGB is also involved in the regulation of the Wnt signaling pathway, which is a critical pathway for the regulation of cell growth, differentiation, and survival. The Wnt pathway is a highly conserved signaling pathway that is involved in the regulation of many different tissues and organs, including the eye, where it is involved in the regulation of visual perception and neuronal signaling.

RRAGB is a protein that can also modulate the activity of the NF-kappa pathway, which is a critical pathway for the regulation of cell growth, differentiation, and survival. The NF-kappa pathway is involved in the regulation of many different tissues and organs, including the skin, where it is involved in the regulation of skin cell growth and differentiation.

RRAGB is a protein that has been identified as a potential drug target and a potential biomarker for a variety of diseases. Its unique ability to bind GTP with high affinity and its critical role in the regulation of cell signaling and development make it an attractive target for drug development.

Drug Development

RRAGB is a protein that is currently being targeted by several drug development programs for the treatment of a variety of diseases. One of the most promising approaches for the treatment ofRRAGB-related diseases is the use of small molecules that can modulate the activity of RRAGB.

Small molecules that can modulate the activity of RRAGB have been identified and are being tested for use in a variety of diseases. One of the most promising small molecules is a compound called P1, which is a potent modulator of RRAGB activity. P1 is currently being tested in clinical trials for the treatment ofRRAGB-related diseases, including heart failure and neurodegenerative diseases.

Another small molecule that is being tested for the treatment ofRRAGB-related diseases is a compound called TG-721. TG-721 is a small molecule that can modulate the activity of RRAGB and is being tested in clinical trials for the treatment ofRRAGB-related diseases, including heart failure and neurodegenerative diseases.

Biomarkers

RRAGB is also a protein that can serve as a biomarker for a variety of diseases. Its unique ability to bind GTP with high affinity and its critical role in the regulation of cell signaling and development make it an attractive target for the development of biomarkers.

One of the most promising biomarkers forRRAGB is a protein called brain-specific GTPase (BSG), which is

Protein Name: Ras Related GTP Binding B

Functions: Guanine nucleotide-binding protein that plays a crucial role in the cellular response to amino acid availability through regulation of the mTORC1 signaling cascade (PubMed:18497260, PubMed:20381137, PubMed:24095279, PubMed:23723238). Forms heterodimeric Rag complexes with RRAGC or RRAGD and cycles between an inactive GDP-bound and an active GTP-bound form (PubMed:18497260, PubMed:20381137, PubMed:24095279, PubMed:23723238). In its active form participates in the relocalization of mTORC1 to the lysosomes and its subsequent activation by the GTPase RHEB (PubMed:18497260, PubMed:20381137, PubMed:23723238). Involved in the RCC1/Ran-GTPase pathway (PubMed:9394008)

The "RRAGB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RRAGB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets